Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F16%3A43911150" target="_blank" >RIV/00216208:11120/16:43911150 - isvavai.cz</a>
Alternative codes found
RIV/75010330:_____/16:00011409 RIV/00216208:11110/16:10327723
Result on the web
<a href="http://dx.doi.org/10.1165/rcmb.2015-0315OC" target="_blank" >http://dx.doi.org/10.1165/rcmb.2015-0315OC</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1165/rcmb.2015-0315OC" target="_blank" >10.1165/rcmb.2015-0315OC</a>
Alternative languages
Result language
angličtina
Original language name
Inhibition of Lipolysis Ameliorates Diabetic Phenotype in a Mouse Model of Obstructive Sleep Apnea
Original language description
Obstructive sleep apnea (OSA) is associated with insulin resistance, glucose intolerance, and type 2 diabetes. Causal mechanisms mediating this association are not well defined; however, augmented lipolysis in adipose might be involved. Here, we investigated the effect of acipimox treatment (lipolysis inhibitor) on glucose tolerance and insulin sensitivity in mice exposed to intermittent hypoxia (IH). C57BL6/J mice were exposed for 14 days to IH or control conditions. IH was created by decreasing the Fraction of Inspired Oxygen (FiO2) from 20.9% to 6.5%, 60 times/hr. Control exposure, was air (FiO2 = 20.9%) delivered at an identical flow rate. Acipimox was provided in drinking water (0.5 g/mL) during exposures. Following exposures, intraperitoneal insulin (0.5 IU/kg) was measured and glucose (1g/kg) tolerance tests were performed and primary adipocytes were isolated for lipolysis experiments. IH elevated fasting glucose by 51% and worsened glucose tolerance and insulin sensitivity by 33% and 102%, respectively. In parallel, IH increased spontaneous lipolysis by 264%, reduced epididymal fat mass by 15% and adipocyte size by 8%. Acipimox treatment prevented IH-induced lipolysis and increased epididymal fat mass and adipocytes size by 19% and 10%, respectively. Acipimox fully prevented IH-induced impairments in fasting glycemia, glucose tolerance, and insulin sensitivity. For all reported results, p < 0.05 was considered significant. Augmented lipolysis contributes to insulin resistance and glucose intolerance observed in mice exposed to IH. Acipimox treatment ameliorated the metabolic consequences of IH and might represent a novel treatment option for OSA patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FB - Endocrinology, diabetology, metabolism, nutrition
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
American Journal of Respiratory Cell and Molecular Biology
ISSN
1044-1549
e-ISSN
—
Volume of the periodical
55
Issue of the periodical within the volume
2
Country of publishing house
US - UNITED STATES
Number of pages
9
Pages from-to
299-307
UT code for WoS article
000381702300015
EID of the result in the Scopus database
2-s2.0-84988934705